National Center for Health Statistics (NCHS), ICD-10 Coordination and Maintenance (C&M) Committee Meeting, 5440-5441 [2020-01756]
Download as PDF
<![CDATA[
5440
Federal Register / Vol. 85, No. 20 / Thursday, January 30, 2020 / Notices
practice-based evidence and issues
recommendations. CPSTF
recommendations are not mandates for
compliance or resource allocation.
Instead, they provide information about
evidence-based options that decision
makers and stakeholders can consider
when they are determining what best
meets the specific needs, preferences,
available resources, and constraints of
their jurisdictions and constituents. The
CPSTF’s recommendations, along with
the systematic reviews of the evidence
on which they are based, are compiled
in the The Community Guide.
Matters proposed for discussion: The
CPSTF will discuss the 2020 process for
establishing its priority topics for 2021–
2025 during a closed session the first
half of the day. During the afternoon
session which is open to the public, the
CPSTF will deliberate on systematic
reviews of literature related to the
following: HIV Prevention: Clinical
Decision Support Systems to Increase
HIV Screening; Cardiovascular Disease
Prevention and Control: Economics of
Pharmacy-Based Interventions to
Increase Medication Adherence; and
one or more proposals for new reviews
in the areas of mental health, sleep
health, tobacco prevention and control.
The agenda is subject to change without
prior notice; however, agenda updates
will be posted on the the Community
Guide website
(www.thecommunityguide.org).
Dated: January 27, 2020.
Sandra Cashman,
Executive Secretary, Centers for Disease
Control and Prevention.
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
RFA–CK–20–004, Prevention Epicenters
Program: Protecting Patients from
Infections, Antibiotics Resistance and
Other Adverse Events.
Date: May 21, 2020.
Time: 10:00 a.m.–5:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, CDC, 1600
Clifton Road NE, Mailstop US8–1,
Atlanta, Georgia 30329–4027;
Telephone: (404) 718–8833; gca5@
cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention
Notice of Closed Meeting
khammond on DSKJM1Z7X2PROD with NOTICES
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
Jkt 250001
[FR Doc. 2020–01621 Filed 1–29–20; 8:45 am]
BILLING CODE 4163–18–P
BILLING CODE 4163–18–P
BILLING CODE 4163–18–P
16:56 Jan 29, 2020
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2020–01620 Filed 1–29–20; 8:45 am]
[FR Doc. 2020–01732 Filed 1–29–20; 8:45 am]
VerDate Sep<11>2014
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
RFA–IP–20–005, Rapid-Cycle Survey
Collaborative for Patient and Provider
Input on Immunization Issues.
Date: April 21, 2020.
Time: 10:00 a.m.–5:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
FOR FURTHER INFORMATION CONTACT:
Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, CDC, 1600
Clifton Road, NE, Mailstop US8–1,
Atlanta, Georgia 30329–4027;
Telephone: (404) 718–8833; gca5@
cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
National Center for Health Statistics
(NCHS), ICD–10 Coordination and
Maintenance (C&M) Committee
Meeting
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
The Centers for Disease
Control and Prevention, National Center
for Health Statistics (NCHS),
Classifications and Public Health Data
Standards Staff, announces the
following meeting of the ICD–10
Coordination and Maintenance (C&M)
Committee meeting. This meeting is
open to the public, limited only by the
space available. The meeting room
accommodates approximately 240
SUMMARY:
E:\FR\FM\30JAN1.SGM
30JAN1
Federal Register / Vol. 85, No. 20 / Thursday, January 30, 2020 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
people. We will be broadcasting the
meeting live via Webcast at https://
www.cms.gov/live/.
DATES: The meeting will be held on
March 17, 2020, 9:00 a.m. to 5:00 p.m.,
EDT and March 18,2020, 9:00 a.m. to
5:00 p.m., EDT.
ADDRESSES: Centers for Medicare and
Medicaid Services (CMS) Auditorium,
7500 Security Boulevard, Baltimore,
Maryland 21244.
FOR FURTHER INFORMATION CONTACT:
Traci Ramirez, Program Specialist, CDC,
3311 Toledo Road, Hyattsville,
Maryland 20782; telephone: (301) 458–
4454; TRamirez@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The ICD–10 Coordination
and Maintenance (C&M) Committee is a
public forum for the presentation of
proposed modifications to the
International Classification of Diseases,
Tenth Revision, Clinical Modification
and ICD–10 Procedure Coding System.
Matters to be Considered: The
tentative agenda will include
discussions on ICD–10–CM and ICD–
10–PCS topics listed below. Agenda
items are subject to change as priorities
dictate.
Please refer to the posted agenda for
updates one month prior to the meeting.
ICD–10–PCS Topics
Microbial Testing
Insertion of Subcutaneous Pump System
for Ascites Drainage
Insertion of Carotid Baroceptor
Stimulator Pulse Generator
Infectious Disease Testing
Administration of BREYANZI®
(lisocabtagene maraleucel)
Administration of FETROJA®
(cefiderocol)
CT Angiogram with Computer-Aided
Triage and Notification
Endoscopic Gastrointestinal Hemostat
Administration of IMFINZI®
(durvalumab)
Intramedullary Joint Fusion System
Peripheral Intravascular Lithotripsy
(IVL)
Administration of KTE–X19
Administration of NUZYRA®
(omadacycline)
Administration of OTL–101
Administration of Sivextro (tedizolid
phosphate)
Administration of Soliris® (eculizumab)
Transcarotid Arterial Revascularization
with Embolic
Neuroprotection
Implantable Fracture Reduction System
Administration of TECENTRIQ®
(atezolizumab)
Administration of TERLIVAZ®
(terlipressin)
Administration of XENLETA®
(lefamulin)
VerDate Sep<11>2014
16:56 Jan 29, 2020
Jkt 250001
Administration of ZERBAXA®
(ceftolozane and tazobactam)
Addenda
ICD–10–CM Topics
Anaplasmosis
Breast implant illness
Cough
Electronic nicotine delivery devices
Endometriosis
Non-ischemic heart disease
Non-radiographic axial
spondyloarthritis
Synthetic cannabinoids
Addenda
Security Considerations: Due to
increased security requirements, CMS
has instituted stringent procedures for
entrance into the building by nongovernment employees. Attendees will
need to present valid government-issued
picture identification, and sign-in at the
security desk upon entering the
building.
Attendees who wish to attend the
March 17–18, 2020, ICD–10–CM C&M
meeting must submit their name and
organization by March 6, 2020, for
inclusion on the visitor list. This visitor
list will be maintained at the front desk
of the CMS building and used by
security to admit visitors to the meeting.
To request reasonable accommodation,
please contact the CMS Reasonable
Accommodation Program at Email
reasonableaccommodationprogram@
cms.hhs.gov.
Participants who attended previous
Coordination and Maintenance meetings
will no longer be automatically added to
the visitor list. You must request
inclusion of your name prior to each
meeting you wish attend.
Please register to attend the meeting
on-line at: https://www.cms.hhs.gov/
apps/events/.
Please contact Mady Hue (410–786–
4510) or Marilu.hue@cms.hhs.gov for
questions about the registration process.
Note: CMS and NCHS no longer
provide paper copies of handouts for the
meeting. Electronic copies of all meeting
materials will be posted on the CMS and
NCHS websites prior to the meeting at
https://www.cms.hhs.gov/ICD9Provider
DiagnosticCodes/03_
meetings.asp#TopOfPage and https://
www.cdc.gov/nchs/icd/icd10cm_
maintenance.htm.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
5441
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2020–01756 Filed 1–29–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease, Disability,
and Injury Prevention and Control Special
Emphasis Panel (SEP)—SIP20–003,
Improving Genetic Counseling Referrals for
Early Onset Colorectal Cancer.
Date: April 24, 2020.
Time: 11:00 a.m.–6:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact: Jaya
Raman Ph.D., Scientific Review Officer, CDC,
4770 Buford Highway, Mailstop F80, Atlanta,
Georgia 30341; Telephone: (770) 488–6511;
kva5@cdc.gov.
The Director, Strategic Business Initiatives
Unit, Office of the Chief Operating Officer,
Centers for Disease Control and Prevention,
has been delegated the authority to sign
Federal Register notices pertaining to
announcements of meetings and other
committee management activities, for both
the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2020–01622 Filed 1–29–20; 8:45 am]
BILLING CODE 4163–18–P
E:\FR\FM\30JAN1.SGM
30JAN1
]]>Agencies
[Federal Register Volume 85, Number 20 (Thursday, January 30, 2020)]
[Notices]
[Pages 5440-5441]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-01756]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
National Center for Health Statistics (NCHS), ICD-10 Coordination
and Maintenance (C&M) Committee Meeting
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention, National
Center for Health Statistics (NCHS), Classifications and Public Health
Data Standards Staff, announces the following meeting of the ICD-10
Coordination and Maintenance (C&M) Committee meeting. This meeting is
open to the public, limited only by the space available. The meeting
room accommodates approximately 240
[[Page 5441]]
people. We will be broadcasting the meeting live via Webcast at https://www.cms.gov/live/.
DATES: The meeting will be held on March 17, 2020, 9:00 a.m. to 5:00
p.m., EDT and March 18,2020, 9:00 a.m. to 5:00 p.m., EDT.
ADDRESSES: Centers for Medicare and Medicaid Services (CMS) Auditorium,
7500 Security Boulevard, Baltimore, Maryland 21244.
FOR FURTHER INFORMATION CONTACT: Traci Ramirez, Program Specialist,
CDC, 3311 Toledo Road, Hyattsville, Maryland 20782; telephone: (301)
458-4454; [email protected].
SUPPLEMENTARY INFORMATION:
Purpose: The ICD-10 Coordination and Maintenance (C&M) Committee is
a public forum for the presentation of proposed modifications to the
International Classification of Diseases, Tenth Revision, Clinical
Modification and ICD-10 Procedure Coding System.
Matters to be Considered: The tentative agenda will include
discussions on ICD-10-CM and ICD-10-PCS topics listed below. Agenda
items are subject to change as priorities dictate.
Please refer to the posted agenda for updates one month prior to
the meeting.
ICD-10-PCS Topics
Microbial Testing
Insertion of Subcutaneous Pump System for Ascites Drainage
Insertion of Carotid Baroceptor Stimulator Pulse Generator
Infectious Disease Testing
Administration of BREYANZI[supreg] (lisocabtagene maraleucel)
Administration of FETROJA[supreg] (cefiderocol)
CT Angiogram with Computer-Aided Triage and Notification
Endoscopic Gastrointestinal Hemostat
Administration of IMFINZI[supreg] (durvalumab)
Intramedullary Joint Fusion System
Peripheral Intravascular Lithotripsy (IVL)
Administration of KTE-X19
Administration of NUZYRA[supreg] (omadacycline)
Administration of OTL-101
Administration of Sivextro (tedizolid phosphate)
Administration of Soliris[supreg] (eculizumab)
Transcarotid Arterial Revascularization with Embolic
Neuroprotection
Implantable Fracture Reduction System
Administration of TECENTRIQ[supreg] (atezolizumab)
Administration of TERLIVAZ[supreg] (terlipressin)
Administration of XENLETA[supreg] (lefamulin)
Administration of ZERBAXA[supreg] (ceftolozane and tazobactam)
Addenda
ICD-10-CM Topics
Anaplasmosis
Breast implant illness
Cough
Electronic nicotine delivery devices
Endometriosis
Non-ischemic heart disease
Non-radiographic axial spondyloarthritis
Synthetic cannabinoids
Addenda
Security Considerations: Due to increased security requirements,
CMS has instituted stringent procedures for entrance into the building
by non-government employees. Attendees will need to present valid
government-issued picture identification, and sign-in at the security
desk upon entering the building.
Attendees who wish to attend the March 17-18, 2020, ICD-10-CM C&M
meeting must submit their name and organization by March 6, 2020, for
inclusion on the visitor list. This visitor list will be maintained at
the front desk of the CMS building and used by security to admit
visitors to the meeting. To request reasonable accommodation, please
contact the CMS Reasonable Accommodation Program at Email
[email protected].
Participants who attended previous Coordination and Maintenance
meetings will no longer be automatically added to the visitor list. You
must request inclusion of your name prior to each meeting you wish
attend.
Please register to attend the meeting on-line at: https://www.cms.hhs.gov/apps/events/.
Please contact Mady Hue (410-786-4510) or [email protected]
for questions about the registration process.
Note: CMS and NCHS no longer provide paper copies of handouts for
the meeting. Electronic copies of all meeting materials will be posted
on the CMS and NCHS websites prior to the meeting at https://www.cms.hhs.gov/ICD9ProviderDiagnosticCodes/03_meetings.asp#TopOfPage
and https://www.cdc.gov/nchs/icd/icd10cm_maintenance.htm.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2020-01756 Filed 1-29-20; 8:45 am]
BILLING CODE 4163-18-P
